• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by ImmunoPrecise Antibodies

    IPA’s Subsidiary BioStrand Unveils Use Case for Solving the Information Integration Dilemma (IID)
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    IPA Releases New HYFT-Powered In Silico Humanization Platform, Aims to Disrupt the Transgenic Animal Model Market
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    IPA's Subsidiary, BioStrand, Solves the Information Integration Dilemma (IID) for Systems Biology
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    IPA to Present at Jefferies Healthcare Conference 2023
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    IPA’s Subsidiary BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ and Accelerates in Silico Drug Discovery Developments
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers BCTX BCTXW IPA TSX:BCT
    NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA TSX-V:IPA
    Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA TSX-V:IPA
    IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA TSX-V:IPA
    Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA TSX-V:IPA
    IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA TSX-V:IPA
    IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA TSX-V:IPA
    IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    Eurofins Discovery and ImmunoPrecise Announce Collaboration to Expand their Antibody Discovery Platform
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    Histopathology Preclinical Data from ImmunoPrecise’s Polytope™ Program Confirms Lung Inflammation Reduction
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    Preclinical Data from ImmunoPrecise’s Drug Pipeline to be Presented During the BIO International Partnering Event
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    ImmunoPrecise Announces Appointment of Dr. Ilse Roodink to the Role of Chief Scientific Officer and Resignation of Dr. Yasmina Abdiche
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    ImmunoPrecise Names Dr. Dion Neame to Strategic Advisory Board
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    ImmunoPrecise Moves SARS-CoV-2 PolyTope™ Cocktail Program’s Path Toward IND Filing
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease
    From ImmunoPrecise Antibodies
    Via Business Wire
    Tickers IPA
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.